In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, on investigational oral anticoagulant discovered by Bristol Myers Squibb. This global alliance combines Bristol Myers Squibb’s long-standing strengths in cardiovascular drug development and commercialisation with Pfizer’s global scale and expertise in this field.